New York Medical College

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

Role: lead

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Role: lead

Defibrotide Dose-escalation for SOS Post-HSCT

Role: lead

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

Role: lead

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Role: lead

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Role: lead

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Role: lead

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Role: lead

SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

Role: lead

CMV CTLs in Neonates With CMV Infection

Role: lead

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Role: lead

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Role: lead

Improving Neck Control in Children With Cerebral Palsy Using Robotics

Role: collaborator

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Role: lead

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Role: lead

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Role: lead

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Role: lead

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Role: lead

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Role: lead

Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized Posturography

Role: lead